temozolomide has been researched along with Triple Negative Breast Neoplasms in 6 studies
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 7.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 3.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| "Zj6413 treated breast cancers (BCs) showed an elevated level of DNA damage evidenced by the accumulation of γ-H2AX foci and DNA damaged related proteins." | 1.43 | Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. ( Chen, J; Chen, X; Ji, M; Jin, J; Xu, B; Xue, N; Zhou, J; Zhou, Q, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Papeo, G | 1 |
| Posteri, H | 1 |
| Borghi, D | 1 |
| Busel, AA | 1 |
| Caprera, F | 1 |
| Casale, E | 1 |
| Ciomei, M | 1 |
| Cirla, A | 1 |
| Corti, E | 1 |
| D'Anello, M | 1 |
| Fasolini, M | 1 |
| Forte, B | 1 |
| Galvani, A | 1 |
| Isacchi, A | 1 |
| Khvat, A | 1 |
| Krasavin, MY | 1 |
| Lupi, R | 1 |
| Orsini, P | 1 |
| Perego, R | 1 |
| Pesenti, E | 1 |
| Pezzetta, D | 1 |
| Rainoldi, S | 1 |
| Riccardi-Sirtori, F | 1 |
| Scolaro, A | 1 |
| Sola, F | 1 |
| Zuccotto, F | 1 |
| Felder, ER | 1 |
| Donati, D | 1 |
| Montagnoli, A | 1 |
| Xiao, G | 1 |
| Lundine, D | 1 |
| Annor, GK | 1 |
| Canar, J | 1 |
| Ellison, V | 1 |
| Polotskaia, A | 1 |
| Donabedian, PL | 1 |
| Reiner, T | 1 |
| Khramtsova, GF | 1 |
| Olopade, OI | 1 |
| Mazo, A | 1 |
| Bargonetti, J | 1 |
| Martínez-Aranda, A | 1 |
| Hernández, V | 1 |
| Picón, C | 1 |
| Modolell, I | 1 |
| Sierra, A | 1 |
| Chen, TC | 1 |
| Cho, HY | 1 |
| Wang, W | 1 |
| Barath, M | 1 |
| Sharma, N | 1 |
| Hofman, FM | 1 |
| Schönthal, AH | 1 |
| Palmieri, D | 1 |
| Duchnowska, R | 1 |
| Woditschka, S | 1 |
| Hua, E | 1 |
| Qian, Y | 1 |
| Biernat, W | 1 |
| Sosińska-Mielcarek, K | 1 |
| Gril, B | 1 |
| Stark, AM | 1 |
| Hewitt, SM | 1 |
| Liewehr, DJ | 1 |
| Steinberg, SM | 1 |
| Jassem, J | 1 |
| Steeg, PS | 1 |
| Zhou, Q | 1 |
| Ji, M | 1 |
| Zhou, J | 1 |
| Jin, J | 1 |
| Xue, N | 1 |
| Chen, J | 1 |
| Xu, B | 1 |
| Chen, X | 1 |
6 other studies available for temozolomide and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; DNA Replication; DNA, Neoplasm; Female; Gain | 2020 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Da | 2013 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dac | 2014 |
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2016 |